Biofil Chemicals & Pharmaceuticals Ltd
Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) last reported results for the quarter ended Jun 2026, with sales of ₹12.35 crore and net profit of ₹0.11 crore. The stock last traded at ₹30.2, a market capitalisation of ₹49.1 crore, on a P/E of 102. Over the past 52 weeks the stock has ranged between ₹25.6 and ₹46.8. Figures are as of 6 Oct 2026 and are not real time.
Biofil Chemicals & Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹30.2
- Market cap
- ₹49.1 cr
- Stock P/E
- 102
- Book value
- ₹13.2
- ROE
- -2.83%
- ROCE
- 2.97%
- Dividend yield
- 0.00%
- 52w high / low
- 46.8/25.6
Metrics as of 6 Oct 2026. Not real time.
Track Biofil Chemicals & Pharmaceuticals Ltd
Cruxal reads every Biofil Chemicals & Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Biofil Chemicals & Pharmaceuticals Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- -5%
- 3 Years
- -2%
- TTM
- 9%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -83%
- 10 Years
- 14%
- 5 Years
- -14%
- 3 Years
- -18%
- 1 Year
- -28%
- 10 Years
- 5%
- 5 Years
- 2%
- 3 Years
- 1%
- Last Year
- -3%
Biofil Chemicals & Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹12.35 cr, up 92.1% from ₹6.43 cr a year earlier. Net profit was ₹0.11 cr, down 95.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.41 | 14.2 | 8.35 | 6.43 | 13.54 | 0.86 | 7.57 | 12.35 |
| Expenses | 2.29 | 13.89 | 8.24 | 6.42 | 13.42 | 0.77 | 7.14 | 12.21 |
| Operating profit | 0.12 | 0.31 | 0.11 | 0.01 | 0.12 | 0.09 | 0.43 | 0.14 |
| OPM % | 4.98% | 2.18% | 1.32% | 0.16% | 0.89% | 10.47% | 5.68% | 1.13% |
| Other income | 0.02 | 0.02 | 0.24 | 2.83 | 0.06 | 0.08 | 0.11 | 0.06 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0 |
| Depreciation | 0.1 | 0.1 | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Profit before tax | 0.03 | 0.22 | 0.26 | 2.76 | 0.11 | 0.1 | 0.47 | 0.13 |
| Tax % | 33.33% | 27.27% | 23.08% | 12.68% | 27.27% | 30.00% | 55.32% | 23.08% |
| Net profit | 0.02 | 0.16 | 0.2 | 2.41 | 0.08 | 0.08 | 0.21 | 0.11 |
| EPS (₹) | 0.01 | 0.10 | 0.12 | 1.48 | 0.05 | 0.05 | 0.13 | 0.07 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Biofil Chemicals & Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 40.04 | 33.4 | 28.4 | 34.32 |
| Operating profit | 2.61 | 0.93 | 1.02 | 1.82 | 1.6 | 1.33 | 1.16 | 0.81 | 0.85 | 0.65 | 0.78 |
| OPM % | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 2.02% | 2.54% | 2.29% | 2.27% |
| Net profit | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.7 | 0.56 | 0.71 | 0.56 | 2.79 | 0.48 |
| EPS (₹) | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.44 | 0.34 | 1.71 | 0.30 |
TTM is the trailing twelve months to the most recent quarter.
Biofil Chemicals & Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
| Reserves | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.93 | 2.51 | 5.29 |
| Borrowings | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.52 | 0.44 | 0.47 | 3.02 |
| Other liabilities | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 28.44 | 31.70 | 18.26 |
| Total liabilities | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 | 42.84 |
| Fixed assets | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.62 | 8.34 | 6.94 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.40 | 38.46 | 42.61 | 35.90 |
| Total assets | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 | 42.84 |
As reported by the company. Total assets equal total liabilities by construction.
Biofil Chemicals & Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.71 | 0.46 | 1.26 | 0.89 | 1.11 | -0.22 | -0.11 | 2.39 | -1.92 | -0.60 |
| Cash from investing | -0.48 | -0.38 | -1.41 | -0.21 | -0.10 | -0.07 | -0.01 | -0.02 | -0.10 | 1.14 |
| Cash from financing | -0.11 | -0.02 | -0.08 | -0.57 | -0.83 | -0.01 | 0.02 | -0.12 | 0.00 | 2.54 |
| Net cash flow | 0.13 | 0.06 | -0.24 | 0.12 | 0.18 | -0.30 | -0.11 | 2.25 | -2.03 | 3.07 |
| Free cash flow | 0.23 | 0.08 | -0.15 | 0.68 | 1.01 | -0.29 | -0.12 | 2.37 | -2.02 | 0.54 |
| CFO / operating profit | 35% | 103% | 134% | 63% | 112% | 8% | 10% | 314% | -205% | 9% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Biofil Chemicals & Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% | 4.12% | 2.97% |
| Debtor days | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 | 301.10 | 418.77 | 354.59 |
| Inventory days | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 | 24.81 | 39.52 | 56.24 |
| Days payable | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 | 268.08 | 366.66 | 239.87 |
| Cash conversion cycle | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 | 57.83 | 91.63 | 170.96 |
| Working capital days | 87.65 | 104.83 | 50.81 | 55.69 | 64.12 | 125.25 | 104.25 | 69.37 | 114.09 | 152.17 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Biofil Chemicals & Pharmaceuticals Ltd shareholding pattern
Promoters held 46.79% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00% and DIIs 0.08%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.82% | 46.82% | 46.82% | 46.82% | 46.79% | 46.79% | 46.79% | 46.79% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% |
| Public | 53.10% | 53.11% | 53.11% | 53.10% | 53.12% | 53.13% | 53.12% | 53.13% |
| No. of shareholders | 26,422 | 26,114 | 25,914 | 25,685 | 25,196 | 24,825 | 25,356 | 24,999 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Biofil Chemicals & Pharmaceuticals Ltd corporate filings
- Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depository and Participants) Regulations, 2018 for the quarter ended 30th September, 2026Company Updatelow impact
- Intimation of closure of Trading window with effect from Thursday, 01st October 2026Insider Trading / SASTlow impact
- Biofil Chemicals and Pharmaceuticals Limited confirms continuation of Independent Director post-AGMCompany Updatelow impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited has announced the outcome of its 41st Annual…
Read the full analysis - Biofil Chemicals and Pharmaceuticals Limited concludes 41st AGM; shareholders approve material related party transactions with Cyano Pharma Private LimitedAGM/EGMlow impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited has successfully concluded its 41st Annual…
Read the full analysis - Biofil Chemicals and Pharmaceuticals Limited concludes 41st Annual General Meeting; approves material related party transactionsAGM/EGMlow impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited has successfully concluded its 41st Annual…
Read the full analysis - Biofil Chemicals & Pharmaceuticals Ltd publishes newspaper notices for upcoming corporate proceedingsCompany Updatelow impact
Cruxal's analysis: Biofil Chemicals & Pharmaceuticals Ltd has published statutory notices in the Free Press…
Read the full analysis - Biofil Chemicals and Pharmaceuticals Limited schedules 41st Annual General Meeting for 23rd September 2026AGM/EGMlow impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited has announced the scheduling of its 41st…
Read the full analysis - Biofil Chemicals & Pharmaceuticals Ltd issues notice for email registration to shareholdersCompany Updatelow impact
Cruxal's analysis: Biofil Chemicals & Pharmaceuticals Ltd has initiated a dispatch of letters to…
Read the full analysis - Biofil Chemicals & Pharmaceuticals Ltd submits Integrated Annual Report for FY 2025-26 and announces 41st AGMOtherslow impact
Cruxal's analysis: Biofil Chemicals & Pharmaceuticals Ltd has filed its Integrated Annual Report for the…
Read the full analysis - Biofil Chemicals and Pharmaceuticals Limited Announces 41st AGM and Seeks Approval for Material Related Party Transactions with Cyano Pharma Private LimitedAGM/EGMmedium impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited has scheduled its 41st Annual General…
Read the full analysis - Biofil Chemicals and Pharmaceuticals Limited announces 41st Annual General Meeting (AGM) to be held via Video ConferencingCompany Updatelow impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited has issued a formal notice for its 41st…
Read the full analysis - Biofil Chemicals and Pharmaceuticals Limited reports Q1 FY2027 financial resultsCompany Updatelow impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited has published its unaudited financial…
Read the full analysis - Biofil Chemicals and Pharmaceuticals Limited announces continuation of Independent Director post-age 75Company Updatelow impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited has disclosed the board's approval for the…
Read the full analysis - Biofil Chemicals Q1 FY27 Results: Revenue Growth Driven by Trading, Profitability Declines SharplyBoard Meetinghigh impact
Cruxal's analysis: Biofil Chemicals and Pharmaceuticals Limited reported a significant increase in revenue…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.